Having trouble accessing articles? Reset your cache.

Tivozanib: Completed Phase III enrollment

Aveo completed enrollment of 500 patients in an open-label, international Phase III trial

Read the full 139 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE